Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laureate Pharma, a full- service biopharmaceutical development and protein production company, has entered into a cGMP contract manufacturing agreement with Tolerx, a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases.
Subscribe to our email newsletter
Under the agreement, Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications.
Robert Broeze, president and CEO of Laureate, said: “The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market. With our monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives.”